Apellis Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026The company was bought and is no longer publicly traded, so shareholders' ownership changed completely.
Quarterly earnings show how much money the company made and spent during the first three months of the year.
Changes to employee severance rules affect what workers earn if they leave the company.
A larger pharmaceutical company bought Apellis, which means shareholders' stake in the company will change hands.
A new experienced leader joined the board to help guide company decisions.
Annual earnings report shows total revenue, expenses, and profits for the entire year to assess company health.
Stocky reads Apellis Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Apellis Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 14 May 2026: Biogen completes acquisition, Apellis becomes wholly owned subsidiary.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.